• History of Dana-Farber/Boston Children's

    The Hematology/Oncology Program at Boston Children's Hospital was formed in 1946 and is among the oldest in the country. It was founded by Dr. Louis K. Diamond, who is often said to have been the father of Pediatric Hematology, and by Dr. Sidney Farber, who originated cancer chemotherapy. The modern program dates from 1967 when Dr. David G. Nathan replaced Dr. Diamond as Division Chief. Under his direction the program expanded from a faculty of 3 and 1,200 net square feet (nsf) of research space to a faculty of 21 and 12,000 nsf. During that time, the division also greatly expanded its clinical activities. Following the death of Dr. Farber in 1974, Dr. Nathan assumed responsibil­ity for all Pediatric Oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute (DFCI). Soon thereafter, a bone marrow transplant (BMT) program was begun. In 1985, Dr. Nathan assumed the role of Chairman of the Department of Pediatrics and Drs. Samuel E. Lux and Steven J. Burakoff were appointed to direct the combined program. Dr. Burakoff moved to New York University in 2000 and was replaced by Dr. Stuart H. Orkin. Dr. David A. Williams, formerly the Chief of the Division of Experimental Hematology at Cincinnati Children’s Hospital and a trainee of this program, was recruited in 2007 as Division Chief at Boston Children's Hospital to replace Dr. Lux, who retired from his position after 23 years of service.

    Since 1974 the clinical program in pediatric Hematology/Oncology has been a joint activity of Dana-Farber Cancer Institute (DFCI) and Boston Children's Hospital (BCH). All outpatient clinical activities for pediatric oncology and Bone Marrow Transplant are housed in the Jimmy Fund Clinic in DFCI. All inpatient clinical activities take place at BCH. All clinical hematology takes place at BCH. A selection committee comprised of faculty from both DFCI and BCH selects fellows from the annual candidate pool. Dr. Williams, as the Division Chief at BCH and Fellowship Program Director, is the Chair of the selection committee.

    The program has continued to grow under Drs. Lux’, Williams’ and Orkin’s leadership. In particular, research space expanded following the addition of a new wing of the Enders research building in 1990 and the move to new space in the DFCI in both 1993 and 1998. A new research building (Karp Building) at BCH that opened in November 2003 allowed the program to expand to approximately 44,000 nsf. Most recently, with Dr. Williams’ recruitment, an additional 3400 nsf of space was added to the Division in the 4th floor of the Life Sciences Building Boston (LSBB) immediately adjacent to and connected with the Karp Building, giving the division >47,000 nsf of research space. This represents >320 laboratory benches. The research space is connected to the Stem Cell Program at BCH (Dr. Len Zon, Director) and to the Immune Disease Institute (Dr. Fred Alt, Director). These programs are integral parts of this training. An additional 5,000 nsf of research space is included in Dr. Williams’ recruitment package for future expansion which has not yet come on line. Dr. Williams brings new expertise in translational research, particularly focused on stem cell biology and genetic therapies.

    Training record

    The "graduates" of the fellowship program during the past 40 years best illustrate the success of our approach to training: 95% are in academic medicine and 61% are doing primarily laboratory or clinical research (or are administering research). Another way to look at the program is to analyze our success at achieving our major objective, which is to train leaders of American hematology and oncology. To evaluate our success in preparing fellows for leadership positions, one must consider the cohort who began training between 1966 and 1992. More recent fellows are still completing their training or are early in their academic careers.

    Leadership positions:

    Trainees of the program have a stellar academic record and the vast majority remain in academic Hematology/Oncology positions. For those of our graduates who began the program between 1965 and 1989:

    Thus, 83% of the alumni in academic medicine are in positions of prominence. An additional 9 individuals (8%) are Leaders in the Biotechnology/Biopharmaceutical Industry. More than 30% percent of those program alumni who began between 1990 and 2000 are in leadership positions, but many are still young and have not reached their full potential. So far 58 of the 60 graduates remain in academic medicine and a high percentage are pursuing careers in laboratory research. In addition, the percentage of 1990-2000 trainees who have finished their training and been selected as tenure track (Asst Prof or higher) faculty members is 93%. This is very similar to the 1965 -1989 cohort (88%) and predicts continued academic success of our trainees.

    • 72 graduates (68%) are currently Professors or Professor Emeritus of Pediatrics, Medicine or a related field.
    • 36 graduates (34%) are current or emeritus Deans, Senior Medical School Administrators, Hospital or Institute Directors or Department Chairs
    • 37 graduates (34%) are current or emeritus Chiefs of Divisions of Hematology, Oncology, Hematology/Oncology, Bone Marrow Transplantation or Other Divisions
    • 13 graduates (12%) are Research Professors or Directors of Research
    • 11 graduates (10%) are Heads of Major Clinical Programs

    Select societies

    A remarkable number of the graduates of our fellowship program or our other trainees are members of the institutions that guide American medicine and pediatrics and that select their members based on scientific accomplishment. No other pediatric program, in any specialty, has such a record of accomplishment by its alumni.

    • National Academy of Sciences and/or the Academy's Institute of Medicine - 14 members
    • American Academy of Arts and Sciences - 6 members Howard Hughes Medical Institute - 11 members
    • Association of American Physicians - 32 members
    • American Pediatric Society - 46 members
    • American Society of Clinical Investigation - 55 members
    • Society for Pediatric Research - 75 members

    Five alumni have served as President of the American Society of Clinical Investigation and one as Vice President. Five have served as President of the American Society of Hematology. Four have been President of the American Society of Pediatric Hematology/Oncology (Holcombe Grier is this year's president). Six were awarded the prestigious Dameshek Prize for Research in Hematology, four received the equally prestigious E. Donnall Thomas Prize in Hematology, and 8 received the E. Mead-Johnson Award for Research in Pediatrics. These are the highest awards in each specialty. Two received Ash Mentor Awards which has only been given for three years. Five have won the Young Investigator Award of the Society for Pediatric Research. Four received the Henry M. Stratton Medal in recognition of a distinguished career in American Hematology. Six have received Distinguished Career Award of the American Society of Pediatric Hematology/Oncology. Finally, David Nathan, had received the Howland Award, the highest honor in Pediatrics and Kober Medal, the highest honor in internal medicine.


    • Herbert T. Abelson, M.D. (Assoc Dean for Admissions and ex-Chair, Dept. of Pediatrics, Chicago; ex-Chair, Univ. of Washington, Seattle)
    • Nancy C. Andrews, M.D., Ph.D. (Dean, Duke University School of Medicine; previously, Dean for Basic Science & Graduate Studies and HHMI Investigator, Harvard Medical School)
    • Robert J. Arceci, M.D., Ph.D. (ex-Chief, Div. of Pediatric Oncology, Dept. of Oncology, Johns Hopkins)
    • Edward J. Benz Jr., M.D. (President, Dana-Farber Cancer Institute, Harvard; Ex-Chair, Dept. of Medicine, Johns Hopkins)
    • Eric C. Beyer, M.D., Ph.D. (ex-Chief, Div. of Pediatric Hematology/Oncology, Chicago)
    • Barbara Bierer, M.D. (Senior Vice President for Research, Brigham and Women's Hospital, Harvard)
    • Laurence A. Boxer, M.D. (ex-Chief, Div. of Pediatric Hematology/Oncology, Michigan)
    • George Buchanan, M.D. (Chief, Div. of Pediatric Hematology/Oncology, Texas, Southwestern)
    • Steven J. Burakoff, M.D. (Director, Skirball Institute of Biomolecular Medicine, New York Univ; ex-Chai, Ped Oncology, Dana-Farber Cancer Institute)
    • Bruce M. Camitta, M.D. (ex-Chief, Section of Pediatric Hematology/Oncology, Milwaukee)
    • Luis Clavell, M.D. (Medical Director, San Jorge Children's Hospital, Univ of Puerto Rico School of Medicine)
    • Harvey J. Cohen , M.D., Ph.D. (ex-Chair, Dept. of Pediatrics, Stanford)
    • Kenneth R. Cooke, MD (Director, Pediatric Blood and Bone Marrow Transplantation, Case Medical Center)
    • John T. Curnutte, M.D., Ph.D. (President, DNAX Research Institute, Vice-President, Schering-Plough Res. Inst.)
    • Alan D. D'Andrea M.D. (Research Director, Dept. of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School)
    • Albert D. Deisseroth, M.D., Ph.D. (President and CEO, Sidney Kimmel Cancer Center, San Diego)
    • Lisa R. Diller, M.D. (Chief of Clinical Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital; Director, Adult and Pediatric Cancer Survivor Program, Dana-Farber Cancer Institute, Harvard)
    • Mary C. Dinauer, M.D. (Professor and Head, Herman Wells Research Center, Dept. of Pediatrics, Indiana)
    • Stephen G. Emerson, M.D., Ph.D. (ex-Chief, Div. of Hematology/Oncology, Dept. of Medicine, Pennsylvania)
    • R. Alan B. Ezekowitz, MBChB, DPhil (Senior Vice President, Merck, Inc., ex-Chair, Dept. of Pediatrics, Massachusetts General Hospital, Harvard)
    • Douglas V. Faller, M.D., Ph.D. (Director, Cancer Research Center; Vice-Chair, Dept of Medicine, Boston Univ)
    • Stephen A. Feig, M.D. (Vice-Chair of Pediatric, UCLA, ex-Chief, Div. of Pediatric Hematology/Oncology)
    • James Ferrara, M.D. (Director, Pediatric Bone Marrow Transplantation, Michigan)
    • Nathan Fischel-Ghodsian, M.D. (Director, Molecular Hematology, Cedars-Sinai Medical Center, Los Angeles)
    • David E. Fisher, M.D., Ph.D. (Director, Melanoma Service, Dana-Farber Cancer Institute, Harvard)
    • Bernard G. Forget, M.D. (Chief, Hematology Section, Dept. of Medicine, Ex-Dean of Science, Sch. of Med., Yale)
    • Christopher Frantz, M.D. (Chief, Div of Hematol/Oncol, Alfred I. duPont Hosp for Children, Wilmington, DE)
    • Stephen H. Friend, M.D., Ph.D. (President, Rosetta Inpharmatics; Senior Vice President for Basic Research, Merck Inc.)
    • Robert Garcea, M.D. (ex-Chief, Div. of Pediatric Hematology/Oncology, Colorado)
    • David Ginsburg, M.D. (HHMI Investigator; ex-Chief, Div. of Molecular Medicine and Genetics, Dept. of Med., Michigan)
    • Bertil E. Glader, M.D. (ex-Chief, Div. of Ped Hematology/Oncology, Stanford)
    • Todd R. Golub, M.D. (Director, Cancer Genomics, Broad Institute and Dana-Farber Cancer Institute, Associate Investigator, HHMI)
    • Jed Gorlin, M.D. (VP and Medical Director, Memorial Blood Centers, Minneapolis)
    • Daniel M. Green, M.D. (ex-Chief, Division of Oncology, SUNY Buffalo)
    • Holcombe E. Grier, M.D. (Assoc Chief of Pediatric Clinical Oncology, Dana-Farber Cancer Institute, Harvard)
    • Yuet W. Kan, M.D. (Chief, Div. of Molec. Med. and Diagnostics; ex-HHMI Investigator, Univ Calif.
    • Mark W. Kieran, M.D., Ph.D. (Head, Neuro-oncology, Children's Hospital/Dana-Farber Cancer Institute)
    • Christoph Klein, M.D. (Head, Section of Exp Hematol, Dept Pediat Hematol/Oncol, Hannover, Germany)
    • Eric C. Larsen, M.D. (ex-Director, Div. of Pediatric Hematology/Oncology, Dartmouth)
    • Michael P. Link, M.D. (Chief, Div of Pediatric Hematology/Oncology, Stanford)
    • Jeffrey Lipton, M.D., Ph.D. (Chief, Div. of Pediatric Hematology/Oncology, Long Island Jewish Med. Ctr, NY)
    • Bertram H. Lubin, M.D. (Director of Medical Research, Oakland Children's Hospital, Oakland, CA)
    • Samuel E. Lux, M.D. (Vice Chair for Science; ex-Chief, Div of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School)
    • William C. Mentzer, M.D. (ex-Chief, Div. of Pediatric Hematology/Oncology, Univ Calif, San Francisco)
    • Ellis J. Neufeld, M.D., Ph.D. (Assoc. Director of Hematology, Boston Children's Hospital, Harvard Medical School)
    • Peter E. Newburger, M.D. (Chief, Div. of Pediatric Hematology/Oncology, Univ Massachusetts)
    • Charlotte Niemeyer, M.D. (Professor and Head of Oncology, Univ. Children's Hospital, Freiburg, Germany)
    • Arthur W. Nienhuis, M.D. (ex-Director & CEO, St. Jude Children's Research Hospital, Memphis)
    • Stuart H. Orkin, M.D. (Chair, Dept of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard; Investigator, HHMI)
    • Robertson Parkman, M.D. (ex-Chief, Bone Marrow Transplantation Service, Children's Hospital, Los Angeles)
    • Susan K. Parsons, M.D. (Dir, Ctr on Child and Family Outcomes, Inst for Clin Res'rch & Health Policy Studies, New Engl Med Ctr, Tufts)
    • Orah S. Platt, M.D. (Chair, Dept of Laboratory Medicine, Children's Hospital, Master, Castle Society, Harvard Medical School)
    • Edward V. Prochownick, M.D., Ph.D. (Director of Oncology Research, Children's Hospital, Pittsburgh)
    • Philip Rosoff, M.D. (ex-Chief, Div. of Pediatric Hematology/Oncology, Duke)
    • Marc E. Rothenberg, M.D., Ph.D. (Chief, Div of Allergy and Clinical Immunology, Cincinnati)
    • Stephen E. Sallan, M.D. (Chief of Staff and ex-Chief of Pediatric Clinical Oncology, Dana-Farber Cancer Institute, Harvard Med School)
    • Charles Scher, M.D. (Chief, Div of Hematology/Oncology, Tulane)
    • Alan L. Schwartz, M.D., Ph.D. (Chair, Dept. of Pediatrics, Washington Univ., St. Louis)
    • Elias Schwartz, M.D. (ex-Director, Med. Res., Dupont Children's Hosp; Ex-Chair, Dept of Pediatrics, CHOP)
    • George B. Segel, M.D. (Vice-Chair of Pediatrics, ex-Chief, Div. of Pediatric Hematology/Oncology, Vice-Chair of Pediatrics, Rochester)
    • Eilat Shinar, M.D. (Director, Israel Red Cross)
    • Susan Shurin, M.D. (Deputy Director, NHLBI; ex-Chief, Div. of Pediatric Hematol/Oncol, Case-Western Reserve)
    • M. Celeste Simon, Ph.D. (HHMI Investigator, Univ Pennsylvania Cancer Center, Philadelphia)
    • Thomas P. Stossel, M.D. (ex-Chief, Div. of Hematology, Dept. of Med., Brigham and Women's Hosp, Harvard)
    • Douglas Taylor, M.D. (Director, Pediatric Hematopoietic Stem Cell Transplantation, Univ California, Davis)
    • Alan S. Wayne, M.D. (Head, Hematologic Diseases Section, Pediatric Oncology Branch, NCI, NIH)
    • Howard J. Weinstein, M.D. (Chief, Div. of Pediatric Hematology/Oncology, Mass. General Hospital, Harvard)
    • Daniel C. West, M.D. (Director, Residency Training Program, Univ California, Davis)
    • David A. Williams, M.D. (Chief, Div. of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School; ex-HHMI Invest.)
    • David B. Wilson, M.D., Ph.D. (ex-Chief, Div. of Pediatric Hematology/Oncology, Washington Univ., St. Louis)
    • Lawrence C. Wolfe, M.D. (Chief, Div. of Pediatric Hematology/Oncology, New Engl Med Ctr, Tufts)
    • Leonard I. Zon, M.D. (Chief, Program in Stem Cell Biology, Investigator, HHMI, Boston Children's Hospital, Harvard)
  • Contact Us

    For questions regarding our fellowship program, please contact Fellowship Program Coordinator Sarah Johnson at 617-919-4242 or email sarah.johnson@childrens.harvard.edu.
  • Fellowship Brochure


    Learn everything you need to know about our Fellowship Program in this detailed brochure. Get information on salary, benefits the application process and much more.

  • Outstanding Care

    Dr. Stuart Orkin, Chair of Pediatric Oncology, describes the unparalleled resources available at Dana-Farber/Boston Children's.